Please login to the form below
Inovio
This page shows the latest Inovio news and features for those working in and with pharma, biotech and healthcare.
Inovio hit with FDA hold on COVID-19 vaccine trial
The US Food and Drug Administration (FDA) has placed a temporary hold on Inovio Pharmaceuticals’ mid-to-late stage coronavirus vaccine trial. ... Importantly, the clinical hold is not due to the occurrence of any adverse events related to the vaccine,
Latest news
-
CEPI says $2bn is needed for COVID-19 vaccine development
CEPI has already invested $4.4m in partnering agreements with Novavax and The University of Oxford to rapidly develop COVID-19 vaccine candidates, and it also announced initial funding to Inovio
-
Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer
Results at six months demonstrated 75% of patients were progression-free. A combination of three cancer immunotherapy drugs from Inovio and Sanofi/Regeneron has shown impressive results in glioblastoma multiforme (GBM), ... Newly-diagnosed GBM patients
-
Takeda gets FDA fast-track status for Zika vaccine
Last year Inovio Pharma and GeneOne Life Sciences reported phase I data with their synthetic GLS-5700 DNA vaccine in the New England Journal of Medicine (NEJM), concluding that it was
-
AZ adds cancer vaccine to immuno-oncology portfolio
AstraZeneca has signed a strategic-level licensing deal with Inovio for cancer vaccines that flesh out its cancer immunotherapy pipeline. ... The result is what Inovio claims is a 'best-in-class' T cell-stimulating therapy, generating fully functional
-
MERS-CoV deaths rise with few drugs in pipeline
Among the small number of companies developing potential vaccines against MERS are Inovio Pharmaceuticals and partner company GeneOne Life Sciences, which recently announced plans to start a phase I trial of
More from news
Approximately 3 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
COVID-19: the race to find a vaccine
Inovio Pharmaceuticals began testing its plasmid candidate in humans in April, putting it at the head of a pack of six groups that have DNA vaccines in development.
-
Developing a COVID-19 vaccine
The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a
-
Deal Watch February 2017
Amendment to 2015 agreement. 80. Inovio Pharmaceuticals/ ApolloBio Corporation. VGX-3100, DNA immunotherapy to treat pre-cancers caused by human papillomavirus (phase II).
-
Pharma deals in August 2015
AstraZeneca deals. Subject. Headline $m. Inovio. Cancer vaccines. 727. Heptares. HTL 1071 and A2A receptor blocking compounds. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for cervical and head &neck cancer.
-
Deal Watch table for September 2013
483. BioFire Diagnostics / BioMerieux. Acquisition. Invitro diagnostic company. 450. Inovio Pharma / Roche Holdings.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Medical Editor
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
- PHE study finds people who have had COVID-19 can still transmit the virus
- Sinovac’s COVID-19 vaccine appears safe in older adults
- PHE study finds people who have had COVID-19 can still transmit the virus
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- New study identifies drugs that are safe to use in COVID-19 treatment
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- Onyx Health Celebrates Its 10th Anniversary with Five New Hires
- Merck’s appeal to restore hepatitis C patent verdict against Gilead fails
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Trial combining British and Russian COVID-19 vaccines could begin in February
- New Oxford research institute established to tackle antimicrobial resistance
- EU proposes vaccine-sharing mechanism with low-income countries
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
- The search for effective drug treatments for COVID-19
- PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
Quick links
Infographics
